Figg WD - Search Results

1

Drug-induced lupus associated with COL-3: report of 3 cases.

Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Ghate JV, et al. Among authors: figg wd. Arch Dermatol. 2001 Apr;137(4):471-4. Arch Dermatol. 2001. PMID: 11295928 Clinical Trial.

2

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.

Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. Figg WD, et al. Cancer. 1995 Apr 15;75(8):2159-64. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o. Cancer. 1995. PMID: 7535186 Clinical Trial.

3

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Figg WD, et al. Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4. Am J Med. 1995. PMID: 7535978 Clinical Trial. No abstract available.

4

Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells.

Danesi R, Figg WD, Reed E, Myers CE. Danesi R, et al. Among authors: figg wd. Mol Pharmacol. 1995 Jun;47(6):1106-11. Mol Pharmacol. 1995. PMID: 7603448

5

A preliminary risk-benefit assessment of paclitaxel.

Bitton RJ, Figg WD, Reed E. Bitton RJ, et al. Among authors: figg wd. Drug Saf. 1995 Mar;12(3):196-208. doi: 10.2165/00002018-199512030-00005. Drug Saf. 1995. PMID: 7619331 Review.

6

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.

Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Bitton RJ, et al. Among authors: figg wd. J Clin Oncol. 1995 Sep;13(9):2223-9. doi: 10.1200/JCO.1995.13.9.2223. J Clin Oncol. 1995. PMID: 7666080 Clinical Trial.

7

Assay of the antiangiogenic compound TNP-470, and one of its metabolites, AGM-1883, by reversed-phase high-performance liquid chromatography in plasma.

Figg WD, Yeh HJ, Thibault A, Pluda JM, Itoh F, Yarchoan R, Cooper MR. Figg WD, et al. J Chromatogr. 1994 Feb 11;652(2):187-94. doi: 10.1016/0378-4347(93)e0388-7. J Chromatogr. 1994. PMID: 8006103

8

Acute renal toxicity associated with suramin in the treatment of prostate cancer.

Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Figg WD, et al. Cancer. 1994 Sep 1;74(5):1612-4. doi: 10.1002/1097-0142(19940901)74:5<1612::aid-cncr2820740519>3.0.co;2-q. Cancer. 1994. PMID: 8062193

9

Hypothyroidism associated with aminoglutethimide in patients with prostate cancer.

Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Figg WD, et al. Arch Intern Med. 1994 May 9;154(9):1023-5. Arch Intern Med. 1994. PMID: 8179445

10

Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.

Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA. Kohn EC, et al. Among authors: figg wd. Cancer Res. 1996 Feb 1;56(3):569-73. Cancer Res. 1996. PMID: 8564973 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

793 results

Search Page

Filters